



národní
úložiště
šedé
literatury

^1H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer.

Michálková, Lenka
2019

Dostupný z <http://www.nusl.cz/ntk/nusl-395969>

Dílo je chráněno podle autorského zákona č. 121/2000 Sb.

Tento dokument byl stažen z Národního úložiště šedé literatury (NUŠL).

Datum stažení: 10.04.2024

Další dokumenty můžete najít prostřednictvím vyhledávacího rozhraní nusl.cz.

¹H NMR Metabolomic Blood Plasma Analysis for Early Detection of Pancreatic Cancer

*Student: Lenka Michálková MSc.
Supervisor: doc. Ing. Vladimír Setnička, Ph. D.
Supervising Expert: Ing. Jan Sýkora, Ph. D.*

Pancreatic cancer (PC) has very high mortality, only 5% of patients survive longer than 3–5 years, this is mostly due to late diagnosis.¹ Nowadays, the PC diagnosis is mainly limited by non-specific early symptoms (weakness, nausea, or abdominal pain) and methods with low sensitivity and specificity.² Consequently, early specific symptoms and characteristic biomarkers remain a subject of intensive research.

In our study, ¹H NMR metabolomics was used to identify changes in the concentration of low molecular metabolites in the blood plasma of healthy controls, pancreatic cancer patients, long term type 2 diabetes mellitus patients and individuals with new-onset diabetes. Using ChenomX software, it was possible to quantify 65 metabolites across all samples. Subsequently, a statistical analysis (PCA, OPLS-DA, *t*-test and Wilcoxon rank sum test) of the concentrations was performed to distinguish the studied groups and to propose a biomarker panel for PC. Moreover, the statistical discrimination allowed to predict new-onset diabetic patients at risk of developing PC. To validate the obtained prediction model, the Monte Carlo cross-validation was performed.

Acknowledgment

The work was realized within Grant No. 16-31028A provided by the Ministry of Health of the Czech Republic and Specific University Research MSMT no. 21-SVV/2019.

References

1. Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2017. *CA: Cancer J. Clin.* **2017**, 67 (1), 7–30.
2. Poruk, K. E.; Firpo, M. A.; Adler, D. G.; Mulvihill, S. J., Screening for pancreatic cancer: why, how, and who? *Ann. Surg.* **2013**, 257 (1), 17–26.